Which company produces Lusutrombopag and analysis of drug sales channels

Lusutrombopag is an oral thrombopoietic drug used to treat preoperative thrombocytopenia in patients with chronic liver disease. The international original manufacturer of this drug is jointly developed and produced by multiple pharmaceutical companies in Japan. It has a solid research and development background and has been proven through multiple clinical trials to be safe and effective in increasing platelet levels and reducing the need for blood transfusions before invasive procedures. The original drug is fully guaranteed in terms of production technology, quality control and clinical data, and is one of the first-choice drugs for clinical use.

In the domestic market, Rutrombopag has been officially launched for sale, and patients can purchase it through hospital pharmacies or approved drug supply channels. Drugs are usually sold in the form of oral tablets, and each box contains multiple tablets. The price of a box is about three to four thousand yuan. Since the drug has been included in the medical insurance, if the patient meets the reimbursement conditions, he or she can obtain a certain proportion of cost reimbursement according to the latest policy of the Medical Insurance Bureau, thereby reducing the financial burden. The specific reimbursement ratio must refer to the latest regulations of the local medical insurance bureau.

In overseas markets, generic drugs of Rutrombopag are also available on the market. For example, the generic version produced in Laos costs about more than 1,000 yuan per box. Generic drugs are basically the same as the original drugs in terms of ingredients, but the production process and clinical data support may be different. When purchasing overseas, you usually need to go through regular pharmacies or medical institutions to ensure that the source of the medicine is legal and reliable, and pay attention to dosage and usage specifications to ensure efficacy and safety.

Generally speaking, Rutrombopag has supply channels at home and abroad, but there are differences in the production process, clinical data and regulatory standards between the original drug and the generic drug. Domestic patients can give priority to obtaining original drugs through hospital pharmacies, and combine with medical insurance policies to reduce costs. At the same time, they must strictly follow the doctor's instructions and regularly monitor platelet levels and related indicators. Although overseas or generic drugs are cheaper, they still require a doctor's guidance before use to ensure safety and efficacy.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/26666417/